Description
Product Availability: In Stock (delivery within 2-3 business days, no extra charge for drop-shipping).
Ordering: To place an order via credit card or PO use Add to Cart button (creating an account is not required).
Transfection Reagent for Neuro-2a Cells (Neuroblastoma Cells, CCL-131)
- Proprietary cationic lipids formulation
- Effective and robust intracellular delivery
- Kit includes Transfection Enhancer reagent
- Produces consistent results, lot-to-lot, plate-to-plate, and well-to-well
- Work in the presence of serum
- A proven reagent for establishing stable cell lines
- Download in vitro Neuro2a transfection protocol: [PDF]
- Download Neuro2a CRISPR/Cas9 transfection protocol: [PDF]
- Download PowerPoint presentation for Neuro2a cells transfection kit: [PPT]
- Developed and manufactured by Altogen Biosystems
Transfection Efficiency:
Reagent exhibits at least 71% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems Neuro2a Transfection Protocol: [PDF]
Download MSDS: [PDF]
Neuro-2a Cell Line:
Neuroblastoma is the most frequent extracranial solid tumor in children, and roughly half of the patients experience bone metastasis accompanied by bone pain, leading to poor prognosis for those affected. The Neuro-2a cell line was established from brain tissue of an albino house mouse (Mus musculus) with neuroblastoma. These cells exhibit neuronal and amoeboid stem cell morphology, making them uniquely useful for scientific study. Also, the Neuro-2a cell line is susceptible to herpes simplex virus, human poliovirus 1, and vesicular stomatitis virus. Neuro-2a cells have been known to create large amounts of microtubular protein. Neuro-2a cells make for reliable transfection hosts due to their neuronal and amoeboid morphology. Altogen Biosystems offers in vitro transfection reagents delivering satisfactory results, including a liposome formulation Neuro-2a transfection reagent kit for neuroblastoma cells that yields high transfection efficiency and is considered an appropriate host for studying brain tumors.
Data:
Figure 1. Cyclophilin B silencing efficiency was determined by qRT-PCR in Neuro2a cells transfected by Cyclophilin B siRNA or non-silencing siRNA control following the recommended transfection protocol. Cyclophilin mRNA expression levels were measured 48 hours post-transfection. 18S rRNA levels were used to normalize the Cyclophilin B data. Values are normalized to untreated sample. Data are presented as means ± SD (n=6).
Figure 2. Protein expression of Cyclophilin B in Neuro-2a cells. DNA plasmid expressing Cyclophilin B or siRNA targeting Cyclophilin B were transfected into Neuro-2a cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Neuro-2a Transfection Kit
Altogen Biosystems:
Altogen Biosystems is a life sciences company that manufactures over 100 cell type specific and pre-optimized transfection kits, electroporation buffers, and targeted in vivo delivery kits and reagents. Advanced formulation of reagents and optimized transfection protocols provide highly efficient intracellular delivery of biomolecules (proteins, DNA, mRNA, shRNA and siRNA, and small molecule compounds). Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Labs Research Services:
Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
Volume Options:
- 0.5 ml (Catalog #6872)
- 1.5 ml (Catalog #6873)
- 1.5 ml CRISPR (Catalog #2184)
- 8.0 ml (Catalog #7073)
AltogenBiosystems是一家开发和制造用于生命科学研究,药物发现和开发的转染试剂盒的生物技术公司。转染试剂盒针对特定癌细胞系和原代细胞培养进行了优化,可将生物分子有效递送到靶组织中。通过先进的试剂配方和优化的转染方案实现体外(癌细胞系)和体内(动物组织靶向试剂、癌细胞系)递送货物分子,包括质粒DNA,各种类型的RNA(mRNA,siRNA,shRNA,microRNA),蛋白质和小分子研究。
Altogen生命科学公司致力于研发,生产和销售特定细胞系的转染试剂,用于细胞间生物分子的传递,并通过对转染试剂类型的设计将siRNA和质粒DNA有效地转入不同的细胞系和原代细胞内。Altogen公司开发的聚合物,脂质体,纳米粒子为基础的转染技术分别针对分子生物学,组合化学,和细胞生物学而分别应用。Altogen定制服务提供符合GLP要求定制研究服务,包括代稳定的细胞系,细胞银行和冷冻保存,焦磷酸测序,克隆,RNA干扰(RNAi)和基因沉默服务,发展分析,siRNA文库筛选,并转染服务。稳定的肿瘤细胞株和原代细胞的产生,可以是非常昂贵和费时。该公司的细胞培养科学家的细胞株的选择,无论是利息或shRNA表达载体的稳定表达的基因改造。标准的RNAi技术服务,包括设计与合成的siRNA的利益,验证siRNA的沉默效率,siRNA转染条件的优化,使高效的基因沉默细胞系或原代培养细胞的靶基因。转染培养细胞的瞬时或稳定的引入外源性分子和遗传物质(即RNA或DNA),通常是在生物实验室用来研究基因功能,基因表达的调节,生化映射,突变分析,和蛋白质的生产。科学家利用各种载体分子,这种分子,使质粒DNA(PDNA),信使RNA(mRNA),短干扰RNA(siRNA),小分子RNA(miRNA)的,并进入肿瘤细胞株和原代细胞的蛋白质的基因交付。不幸的是,无单提货的方法或转染试剂,可以适用于所有类型的细胞,细胞的细胞毒性和转染效率显着不同,取决于试剂,协议,并正在利用细胞类型。Altogen生物系统公司提供超过60种类型的细胞的预优化转染试剂盒。纳米粒子,脂质和聚合物基ALTOGEN®在体内转染试剂,使交付功能的RNA和DNA分子在体内。PEG脂质体在体内输送系统减少由于PEG修饰的先天免疫反应,并提供高效的siRNA转染的DNA,并在体内的蛋白质。由科学“杂志(2010年12月17日):PEG脂质体在体内转染试剂盒siRNA的特色Altogen生物系统功能的特定细胞系转染试剂盒
120+细胞转染试剂和活体组织靶向试剂盒制造商AltogenBiosystems是一家生物技术公司,开发和制造用于生命科学研究、药物发现和开发的转染试剂盒。Altogen®体内转染试剂可有效地将生物分子导入靶组织。细胞转染试剂盒针对特定的癌细胞系和原代细胞进行了优化。通过先进的试剂配方和优化的转染方案实现货物分子(DNA、RNA、蛋白质)的高效传递。AltogenBiosystems利用高分子化学、分子和细胞生物学的专业知识,开发了新的体内外给药技术。转染是将外源分子导入培养细胞中,常用于研究基因功能、基因表达调控、生化定位和蛋白质生产。不幸的是,由于细胞毒性和转染效率的差异很大,并且取决于所使用的试剂、方案和细胞类型,因此没有一种单一的传递方法或转染试剂可应用于所有类型的细胞。AltogenBiosystems为120多个癌细胞系和原代细胞类型提供优化的转染试剂盒和电穿孔产品。体内转染试剂可实现组织靶向给药。Altogen的转染试剂盒包括用于体外(癌细胞系)和体内(用于动物研究的组织靶向试剂)转染的转染增强剂试剂和转染复合物冷凝器。Altogen实验室提供符合GLP的实验室合同研究服务。我们的生物CRO服务包括异种移植物的疗效、IND应用的pharm/tox研究和安全性测试、分析开发(ELISA、IC-50、qPCR)、90多个异种移植物动物模型、RNAi和基因沉默服务。Altogen的细胞培养科学家通过在28天内培育出稳定的细胞系,将选择的细胞系转化为稳定表达感兴趣的基因。
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
免疫组织化学又称免疫细胞化学,是指带显色剂标记的特异性抗体在组织细胞原位通过抗原抗体反应和组织化学的呈色反应,对相应抗原进行定性、定位、定量测定的一项新技术。它把免疫反应的特异性、组织化学的可见性巧妙地结合起来,借助显微镜的现像和放大作用,在细胞,亚细胞水平检测各种抗原物质,并可在原位显示相应的基因和基因表达产物。免疫组织化学技术现已有:免疫荧光组织(细胞)化学技术、免疫酶组织(细胞)化学技术、亲和组织化学技术、免疫金银及铁标记免疫组织化学技术等。免疫荧光组织(细胞)化学技术是采用荧光素标记的已知抗体(或抗原)作为探针,检测待测组织、细胞标本中的靶抗原(或抗体),形成的抗原抗体复合物上带有荧光素,在荧光显微镜下,由于受高压汞灯光源的紫外光照射,荧光素发出明亮的荧光,这样就可以分辨出抗原(或抗体)的所在位置及其性质,并可利用荧光定量技术计算抗原的含量。以达到对抗原物质定位、定性、定量测定的目的。
Bone Mesenchymal Stem Cells 作为一个细胞群体,还没有发现有特定细胞表面marker. 对于那些可以代表自我更新和分化的marker, 也不清楚到底要发现哪一个的表达才能确定该细胞就是BMSC。
目前常用的方法,就是采用培养,colony-forming unit-fibroblasts (CFU-F)这个方法。一般BMSC可以24-48小时贴壁。
流式细胞计数,比如STRO-1,但是一般认为STRO-1阳性的细胞更趋向于造血干细胞,和BMSC简单区别还不是很清楚。
这里有个培养分化的产品
http://www.rndsystems.com/pdf/SC020.pdf
暂无品牌问答